My Ankylosing Spondylitis Diagnosis Journey, Part 2
Second in a series. Read part one. And then the symptoms hit. By 30, I had limited mobility in my back and hips, extremely ... Read more
Updates
-
-
The Joys and Perils of Turning to Online Groups for Support
When I was diagnosed with ankylosing spondylitis (AS), one of the first things I did was join numerous AS groups on Facebook. We’re ... Read more -
TNF-alpha Inhibitors May Increase Eosinophil Levels in Ankylosing Spondylitis Patients, Study Suggests
Use of TNF-alpha inhibitors reduces inflammation and increases levels of eosinophils — a type of immune cell that protects the body from infections — ... Read more -
My Ankylosing Spondylitis Diagnosis Journey, Part 1
First in a series. When I first started having symptoms of ankylosing spondylitis (AS), I was in my mid-20s which is right in ... Read more -
Genetic Marker HLA-B27 Correlates With Ankylosing Spondylitis Onset but Not Disease Burden, Study Shows
The presence of a specific genetic marker called HLA-B27 in Caucasian ankylosing spondylitis patients is related to earlier disease onset and higher disease prevalence among family ... Read more
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
-
Phase 3 Trial Evaluating Xeljanz’s Efficacy in Patients with Active Ankylosing Spondylitis Now Enrolling
Pfizer is recruiting adult patients with active ankylosing spondylitis for a new Phase 3 ... -
Ixekizumab Benefits Ankylosing Spondylitis Patients Who Failed to Respond to Standard Therapy, Phase 3 Study Shows
Ankylosing spondylitis (AS) patients who have failed to respond to standard therapy may benefit ... -
#NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach
With the U.S. midterm elections now less than two weeks away, patient advocacy groups ... -
Filgotinib Safe, Effective in Treating Ankylosing Spondylitis, Phase 2 Trial Shows
Filgotinib, an investigational therapy for ankylosing spondylitis (AS) and other inflammatory diseases, was able to ... -
Cosentyx Safe, Effective Through 5 Years of Treatment, Novartis Announces
Five-year treatment with Cosentyx (secukinumab) is safe and effective in easing signs and symptoms of ankylosing ...
Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows
News
Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more